SAN DIEGO, Aug. 20, 2013 /PRNewswire/ -- SynteractHCR, a full-service, global contract research organization (CRO), will attend and present at three conferences in September and October: Outsourcing in Clinical Trials Nordic, Outsourcing in Clinical Trials Southern California and Outsourcing in Clinical Trials New England. Members of SynteractHCR's senior leadership team will present at the conferences.
Outsourcing in Clinical Trials Nordic will be introduced in Copenhagen, Denmark from September 11-12, to address the expanding biotech in the region. The event is designed to provide a forum for discussing innovative strategies in this growing outsourcing environment. SynteractHCR will exhibit at booth #19. Dr. Francisco Harrison, executive vice president and board member, will serve as the session chairman for day one of the event. Ilari Jauro, director clinical operations, Sweden, will present "Applying Result-driven Techniques to Successfully Transition (and Save) a Failing Study" at 10:00 a.m. CET on Sept. 11th. The presentation will include how to determine when a service provider is not performing and identify when a change in service provider is needed, how to select a new CRO, and how to facilitate a smooth transition that keeps the study on track.
Outsourcing in Clinical Trials Southern California will debut in San Diego on Sept 24-25. The event was designed to support requests in this life science hub. SynteractHCR will exhibit at booth #26. Director of Clinical Technology Services Toby Odenheim, MBA, will give insights on "Electronic Data Capture: The Importance and Impact of Selecting the Optimum EDC Platform for Your Clinical Program." Project Director Barbara Ruby will present "How Doing a Clinical Trial is like Skydiving," which will provide guidelines to establish effective collaboration between CROs and sponsors to achieve optimal working relationships and results.
SynteractHCR will exhibit at booth #55 in the fifth annual event Outsourcing in Clinical Trials New England. Dr. Philip Doren, vice president, biometrics, will present on risk based monitoring at 11:15 a.m. EST on Oct. 1st. Risk-based monitoring has the ability to increase efficiencies of trials by identifying the sources of risk that diminish the objectives of clinical development programs. Dr. Doren will examine how to identify the sources that impose meaningful threats and the actions they might trigger.
SynteractHCR recently introduced its ICD+ platform to leverage the company's deep clinical development expertise, appropriate technology, and optimized execution to drive solution-oriented efficiencies and consistent standards on a global scale. The various programs all speak to elements of this comprehensive methodology and identify ways to take time and cost out of the drug development process.
To set an appointment, contact Matt Smith, SVP business development US at (760) 268-8200.
About SynteractHCR (www.synteracthcr.com)
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. With its "Shared Work – Shared Vision" philosophy SynteractHCR provides customized Phase I through IV services collaboratively and cost effectively ensuring on-time delivery of quality data so clients get to decision points faster. Operating in 16 countries, SynteractHCR delivers trials internationally, offering expertise across multiple therapeutic areas including notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications.